←
Max Kates1,787 posts
Max Kates avatar✓

Max Kates ✓

@MaxKates

Associate Professor of Urology and Oncology Director, Division of Urologic Oncology @bradyurology

◷ Joined May 2014▧ 139 Photos and videos
The Johns Hopkins Brady Urological Institute avatar
⟳ Max Kates retweeted
The Johns Hopkins Brady Urological Institute@brady_urology·Nov 3

Please join us in congratulating Dr. Amin Herati and Dr. Sunil Patel on their promotions to Associate Professor! These well-earned promotions reflect their dedication to exceptional patient care, investment in educating the next generation of physicians, and meaningful research.

Post attachment
Max Kates avatar
Max Kates@MaxKates·Oct 25

For medoncs trying to understand why urologists remain unexcited...issue is the endpoint. Recurrence does not equate progression. Progression does not equate CSS or OS. So we want to at least understand if large/sometime permanent grade 3+ toxicity is worth it. #ESMO26

Max Kates avatar
Max Kates@MaxKates·Oct 25

Neoadjuvant MIBC Trials: KEYNOTE-866 (pembro) and ENERGIZE (nivo)negative. NIAGARA (durva) stands alone. Adjuvant is split too. ICI benefit in MIBC is real but marginal, and likely lives in a subset we have yet to identify. Utilit of chemo+IO less clear in EVP era. #ESMO26

Post attachment
Matt Nielsen, MD avatar
⟳ Max Kates retweeted
Matt Nielsen, MD@m_e_nielsen·Oct 21

Tony is a b r i l l i a n t (!!!!) rising star in urologic oncology (currently NCI UOB via @brady_urology) Timely and excellent work, huge honor to ride his coattails! 🤩🤩🤩❤️🙏

Max Kates avatar
Max Kates@MaxKates·Oct 21

A great read for any of you interested in bladder cancer, nmibc, the nuances of clinical trials and why they matter

Post attachment
Eugene Pietzak avatar
⟳ Max Kates retweeted
Eugene Pietzak@eugene_pietzak·Oct 21

Acknowledging that studies by @MaxKates & others demonstrate BCG retreatment is effective in many selected patients with prior BCG exposure, I just don’t see how one can overcome the inherent selection bias in these retrospective studies to feel confident enough not to explore a subgroup analysis for RCTs enrolling such patients. And even if BCG monotherapy outcomes were comparable, that would not establish that the incremental benefit of adding PD-1/PD-L1 blockade is the same in previously treated and truly BCG-naïve patients. I would argue that in the absence of robust data demonstrating comparable outcomes after BCG retreatment versus first-ever BCG, prior BCG exposure should at minimum be a prespecified subgroup in randomized trials using BCG as the control arm. And if it wasn’t prespecified, the post-hoc analysis is still clinically important. POTOMAC and CREST should report it! • How many patients had prior BCG? • What was the HR in truly BCG-naïve subset? • What was the HR in remotely BCG-exposed patients? 5/n

Eugene Pietzak avatar
⟳ Max Kates retweeted
Eugene Pietzak@eugene_pietzak·Oct 21

The justification for including patients >2–3 years from prior BCG within “BCG-naïve” trials appears to come partly from this @IBCG_BladderCAposition paper, which states that clinical experience suggests their response to BCG retreatment is similar to that of truly BCG-naïve patients While this hasn’t really been my own clinical experience (especially for patients previously treated with maintenance BCG), anecdotal clinical experience is no substitute for objective comparative data, which is precisely why I think reporting on these subgroup analyses is so important. And regardless for a phase III trial with EFS/DFS as the endpoint, what matters is not simply initial response rates, it is the durability of disease control. 4/n @UroDocAsh , @UrogerliMD , @MaxKates ; @pcvblack @pjhensley11, @joanfundi

Post attachment
Max Kates avatar
Max Kates@MaxKates·Oct 14

FDA Approves Anktiva for BCG Unresponsive Papillary Disease. This will be an interesting next few months as other companies seek similar pathway to approval. CIS/papillary buckets a thing of the past? Will certainly make for some good debates... fda.gov/news-events/press-an…

The Johns Hopkins Brady Urological Institute avatar
⟳ Max Kates retweeted
The Johns Hopkins Brady Urological Institute@brady_urology·Oct 5

Thank you to all of the Greenberg Bladder Cancer Institute (@HopkinsGBCI) faculty and national leaders who joined us for the GBCI Fall Retreat. Your commitment to advancing bladder cancer research and patient care made for an inspiring day of collaboration and connection.

Post attachmentPost attachmentPost attachment
UroToday.com avatar
⟳ Max Kates retweeted
UroToday.com@urotoday·Oct 5

Randomized trial of blue light vs white light TURBT with urinary tumor DNA testing. @akfsurgeon @brady_urology & Meghan McNamara, MS @HopkinsMedicine highlight a randomized study pairing blue-light TURBT with UroAmp urinary tumor DNA testing to quantify MRD. Serial testing may better detect residual disease and guide surveillance or treatment intensity. #WatchNow > bit.ly/4v7eEYD

Post attachment
Andrew Gabrielson avatar
⟳ Max Kates retweeted
Andrew Gabrielson@urogabe·Sep 22

Oral boards prep hasn't appreciably changed in decades, so I built MockUro, an AI examiner that walks you through ~250 canonical urology cases in Socratic Q&A format, grades your free-form answers across key domains, and adapts your study plan to your weak spots 🧵

0:30
Max Kates avatar
Max Kates@MaxKates·Aug 6

It really does feel like hospitals in the competitive markets hire mgmt consultants to game this...

Max Kates avatar
Max Kates@MaxKates·Aug 6

Always oddities in US News rankings, but this year it has to be the overemphasis on NYC metro area, with in my count 9 of the top 25 ranked programs in NYC area. Some great ones in NYC for sure, but 9 programs before you even step foot in Nashville, Seattle, Dallas? 🤔